Researchers at the University of Southern California have discovered new compounds that may help reduce brain inflammation linked to Alzheimer’s disease, particularly in individuals with the high-risk APOE4 gene. This inflammation is associated with the activity of an enzyme called cPLA2, which plays a dual role: it can contribute to harmful inflammation while also supporting normal brain function. The newly identified compounds aim to selectively inhibit cPLA2, potentially lowering the risk of Alzheimer’s without disrupting essential brain activities.

This discovery is significant for anyone concerned about aging and cognitive health. If successful, these compounds could offer a way to reduce the risk of Alzheimer’s for people carrying the APOE4 gene, which is the strongest genetic risk factor for the disease. While not all APOE4 carriers develop Alzheimer’s, those with higher levels of cPLA2 activity are at greater risk. The research showed that the compounds reduced cPLA2 activity in brain cells exposed to Alzheimer’s-related stress, suggesting they could play a role in maintaining cognitive function as we age.

The research is still in the early stages, primarily involving cell-based and animal studies. The compounds have shown promise in laboratory settings, effectively crossing the blood-brain barrier and influencing inflammation pathways associated with Alzheimer’s. However, further studies are needed to determine their safety and effectiveness in humans. Researchers are now focused on understanding whether targeting inflammation can meaningfully alter Alzheimer’s risk, especially for those most at risk.

Source: sciencedaily.com